The emergence of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable excitement within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication appears to deliver impressive improvements in weight reduction compared to current therapies. Preliminary research trials have demonstrated significant decreases in body